Application of in silico approaches to predicting drug--drug interactions.

[1]  C. Hansch,et al.  Structure--activity correlations in the metabolism of drugs. , 1968, Archives of biochemistry and biophysics.

[2]  C. Hansch.  Quantitative Relationships Between Lipophilic Character and Drug Metabolism , 1972 .

[3]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[4]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[5]  C. Hansch,et al.  Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.

[6]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[7]  F. Sanz,et al.  Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. , 1993, Molecular pharmacology.

[8]  K. Korzekwa,et al.  Predicting the cytochrome P450 mediated metabolism of xenobiotics. , 1993, Pharmacogenetics.

[9]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[10]  Antti Poso,et al.  Comparative Molecular Field Analysis of Compounds with CYP2A5 Binding Affinity , 1995 .

[11]  C. Hansch,et al.  QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. , 1996, Drug metabolism reviews.

[12]  B G Woodcock,et al.  Systematic screening for pharmacokinetic interactions during drug development. , 1996, International journal of clinical pharmacology and therapeutics.

[13]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[14]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[15]  C. Waller,et al.  Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Dietrich Dörner,et al.  The Logic Of Failure: Recognizing And Avoiding Error In Complex Situations , 1997 .

[17]  D. Lewis,et al.  Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). , 1997, Drug metabolism reviews.

[18]  Barry C. Jones,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .

[19]  Dennis A. Smith,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .

[20]  J. Halpert,et al.  Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. , 1997, Life sciences.

[21]  J. Halpert,et al.  Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[22]  D. Lewis,et al.  Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. , 1998, Toxicology.

[23]  M H Tarbit,et al.  Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. , 1998, Chemico-biological interactions.

[24]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[25]  S. Ekins,et al.  Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.

[26]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[27]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[28]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[29]  S. Ekins,et al.  Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.

[30]  D. Lewis,et al.  On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.

[31]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .

[32]  S. Ekins,et al.  Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.

[33]  S. Ekins,et al.  Present and future in vitro approaches for drug metabolism. , 2000, Journal of pharmacological and toxicological methods.

[34]  Francesca Fanelli,et al.  Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4 , 2000, J. Comput. Aided Mol. Des..

[35]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. , 2000, The Journal of pharmacology and experimental therapeutics.

[36]  G. Szklarz,et al.  Molecular modeling of mammalian cytochromes P450: application to study enzyme function. , 2000, Vitamins and hormones.

[37]  R. Obach,et al.  Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. , 2000, The Journal of pharmacology and experimental therapeutics.

[38]  Jeffrey P. Jones,et al.  A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. , 2000, Journal of medicinal chemistry.

[39]  S. Ekins,et al.  Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[40]  M. Pincus,et al.  Molecular modeling of mammalian cytochrome P450s , 2000, Cellular and Molecular Life Sciences CMLS.

[41]  D. Lewis,et al.  Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.